Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1Breast 1

Conditions

Neuroblastoma 1Epilepsy 1

Interventions

ziprasidone 1perampanel 1clevidipine 1brivaracetam 1Zolpidem 1Warfarin 1Vecuronium Bromide 1Vancomycin 1Tranexamic Acid 1Topotecan 1Tobramycin 1Temozolomide 1Sulfasalazine 1Spironolactone 1Sevoflurane 1Sevelamer 1Saline Solution 1Rocuronium 1Radiotherapy 1Propofol 1Piperacillin, Tazobactam Drug Combination 1Pentobarbital 1Oxycodone 1Nitrous Oxide 1Nifedipine 1Nafcillin 1Molindone 1Methylprednisolone 1Memantine 1Magnetoencephalography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epilepsy × LY3295668 erbumine × CNS × Clear all
NCT04106219 2026-04-21

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Eli Lilly and Company

Phase 1 Active not recruiting
71 enrolled
CNS

Epilepsy, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡